October 20, 2023
Advance Online
Advance Online
FDA Approves BIMZELX®
The first biologic targeting IL-17A and IL-17F is now approved for adults with moderate to severe plaque psoriasis.
The first biologic targeting IL-17A and IL-17F is now approved for adults with moderate to severe plaque psoriasis.
We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.